Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)

PURPOSE: Panitumumab plus FOLFOX (P-FOLFOX) is standard first-line treatment for RAS wild-type (WT) metastatic colorectal cancer. The value of panitumumab rechallenge is currently unknown. We assessed addition of panitumumab to FOLFIRI (P-FOLFIRI) beyond progression to P-FOLFOX in patients with no R...

Descripción completa

Detalles Bibliográficos
Autores principales: Aparicio, Jorge, Virgili Manrique, Anna C., Capdevila, Jaume, Muñoz Boza, Félix, Galván, Patricia, Richart, Paula, Oliveres, Helena, Páez, David, Hernando, Jorge, Serrano, Sara, Vera, Ruth, Hernandez-Yagüe, Xavier, Gallego, Rafael Álvarez, Riesco-Martinez, M. Carmen, García de Albeniz, Xavier, Maurel, Joan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522782/
https://www.ncbi.nlm.nih.gov/pubmed/35761123
http://dx.doi.org/10.1007/s12094-022-02868-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522782/
https://www.ncbi.nlm.nih.gov/pubmed/35761123
http://dx.doi.org/10.1007/s12094-022-02868-x

Ejemplares similares